About Anxiety Disorders
Anxiety is associated with uneasiness, fearfulness, and tension. Mild anxiety, for example, associated with exams or interview, is normal and triggers 'fight or flight' response. Anxiety without an identifiable cause, anxiety which persists even after the stressful condition is over, and anxiety which is out of proportion of the stressful condition indicates abnormal anxiety. However, severe and persistent anxiety can interfere with everyday activities and might lead to other psychic problems. Anxiety disorder is a mental health disorder characterized by the presence of anxiety. These disorders might occur simultaneously with other disorders such as depression, or along with drug abuse.
TechNavio's analysts forecast the Global Anxiety Disorders market to grow at a CAGR of 4.02 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Anxiety Disorders market for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of the following anxiety disorders:
• GAD
• Panic Disorder
• OCD
• PTSD
• Social Anxiety Disorder
• Special Phobias
• BDD
The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Anxiety Disorders market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, Global Anxiety Disorders Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Anxiety Disorders market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Eli Lilly and Company
• GlaxoSmithKline
• Pfizer
Other Prominent Vendors
• Abbott Laboratories
• Actavis
• Baxter International
• F. Hoffmann-La Roche
• Noven Pharmaceuticals
• Recordati Rare Diseases
• Shionogi
• Sumitomo Dainippon Pharma
Market Driver
• Increase in Patient Population
• For a full, detailed list, view our report
Market Challenge
• Poor Diagnoses Rates
• For a full, detailed list, view our report
Market Trend
• Increased Focus on Emerging Markets
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Types of anxiety disorders
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Drug Class
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Eli Lilly
17.2.2 Pfizer
17.2.3 GlaxoSmithKline
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Eli Lilly
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation by Revenue
18.1.4 Sales by Geography
18.1.5 Business Strategy
18.1.6 Key Information
18.1.7 SWOT Analysis
18.2 GlaxoSmithKline
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation
18.2.4 Business Segmentation by Revenue 2012 and 2013
18.2.5 Sales by Geography
18.2.6 Pipeline Products
18.2.7 Business Strategy
18.2.8 Key Information
18.2.9 SWOT Analysis
18.3 Pfizer
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2013
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Geographical Segmentation by Revenue
18.3.6 Business Strategy
18.3.7 Key Developments
18.3.8 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Anxiety Disorders
Exhibit 3: GAD: Disease Overview
Exhibit 4: Panic Disorder: Disease Overview
Exhibit 5: OCD: Disease Overview
Exhibit 6: PTSD: Disease Overview
Exhibit 7: Social Anxiety Disorder: Disease Overview
Exhibit 8: Specific Phobias: Disease Overview
Exhibit 9: BDD: Disease Overview
Exhibit 10: Global Anxiety Disorders Market 2014-2019 (US$ billion)
Exhibit 11: Global Anxiety Disorders Market Segmentation by Drug Class
Exhibit 12: Segmentation of Global Anxiety Disorders Market by Geography 2014
Exhibit 13: Cymbalta: Basic Information
Exhibit 14: Cymbalta Revenue 2011-9M 2014 (US$ million)
Exhibit 15: Revenue Segmentation by Geography 9M 2014
Exhibit 16: Pfizer: Revenue of Key Anti-Anxiety Products 9M 2014 (US$ million)
Exhibit 17: Lyrica: Basic Information
Exhibit 18: Lyrica Revenue 2011-9M 2014 (US$ million)
Exhibit 19: Revenue Segmentation by Geography 9M 2014
Exhibit 20: Zoloft: Basic Information
Exhibit 21: Zoloft Revenue 2011-9M 2014 (US$ million)
Exhibit 22: Revenue Segmentation by Geography 9M 2014
Exhibit 23: Effexor and Effexor XR: Basic Information
Exhibit 24: Effexor/Effexor XR Revenue 2011-9M 2014 (US$ million)
Exhibit 25: Revenue Segmentation by Geography 9M 2014
Exhibit 26: Xanax and Xanax XR: Basic Information
Exhibit 27: Xanax/Xanax XR Revenue 2011-9M 2014 (US$ million)
Exhibit 28: Revenue Segmentation by Geography 9M 2014
Exhibit 29: Seroxat/Paxil/Paxil CR: Basic Information
Exhibit 30: Seroxat/Paxil Revenue 2011-9M 2014 (US$ million)
Exhibit 31: Revenue Segmentation by Geography 9M 2014
Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 34: Eli Lilly: Sales by Geography 2013
Exhibit 35: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 36: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 37: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 38: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 39: Pfizer: Business Segmentation by Revenue 2013
Exhibit 40: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 41: Pfizer: Geographical Segmentation by Revenue 2013
